



# SAFETY DATA SHEET

Revision date 13-Jun-2025

Version 3

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)  
**Product Code(s)** PZ02902  
**Trade Name:** Not applicable  
**Chemical Family:** Not determined

Contains Oxaliplatin

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as Antineoplastic

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

**Germ cell mutagenicity** Category 1B - (H340)  
**Reproductive toxicity** Category 1B - (H360D)

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**  
Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 2 / 13

Version 3

Not applicable

## 2.2. Label elements



### Signal word

Danger

### Hazard statements

H340 - May cause genetic defects  
H360D - May damage the unborn child

### Precautionary Statements - EU (§28, 1272/2008)

P321 - Specific treatment (see . ? on this label)  
P201 - Obtain special instructions before use  
P280 - Wear protective gloves/protective clothing/eye protection/face protection  
P308 + P313 - IF exposed or concerned: Get medical advice/attention  
P202 - Do not handle until all safety precautions have been read and understood

2.5 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.  
2.5 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.  
2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).  
2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).  
2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).

### Unknown aquatic toxicity

Contains 2.5 % of components with unknown hazards to the aquatic environment.

Contains Oxaliplatin

## 2.3. Other hazards

### Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

### Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

### Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
---------------	----------	---------------------------	---------------------	--	------------------------------------	----------	----------------------

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 3 / 13

Version 3

				(EC) No. 1272/2008 [CLP]			
Sodium hydroxide (CAS #: 1310-73-2)	<0.5	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
Oxaliplatin (CAS #: 61825-94-3)	0.5		(607-007-00-3)	Eye Irrit 2A (H319) Repr.1B (H360D) Muta.1B (H340)	Not classified	No data available	No data available

## NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Tartaric acid (CAS #: 87-69-4)	*		201-766-0	Not classified	Not classified	No data available	No data available

## Full text of H- and EUH-phrases: see section 16

## Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Tartaric acid 87-69-4	No data available	2000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 4 / 13

Version 3

## 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

## 4.2. Most important symptoms and effects, both acute and delayed

<b>Most important symptoms and effects</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

## 4.3. Indication of any immediate medical attention and special treatment needed

<b>Note to physicians</b>	None.
---------------------------	-------

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

<b>Suitable Extinguishing Media</b>	Dry chemical, CO <sub>2</sub> , alcohol-resistant foam or water spray.
-------------------------------------	--

### 5.2. Special hazards arising from the substance or mixture

<b>Specific hazards arising from the chemical</b>	Fine particles (such as mists) may fuel fires/explosions.
---	---

<b>Hazardous combustion products</b>	Formation of toxic gases is possible during heating or fire.
--------------------------------------	--

#### Explosion data

<b>Sensitivity to mechanical impact</b>	No information available.
<b>Sensitivity to static discharge</b>	No information available.

### 5.3. Advice for firefighters

<b>Special protective equipment and precautions for fire-fighters</b>	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.
---	--

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

<b>Personal precautions</b>	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
<b>For emergency responders</b>	Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

<b>Environmental precautions</b>	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
----------------------------------	--

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 5 / 13

Version 3

## 6.3. Methods and material for containment and cleaning up

### Methods for containment

Prevent further leakage or spillage if safe to do so.

### Methods for cleaning up

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

### Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

## 6.4. Reference to other sections

### Reference to other sections

See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

#### Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Handle in accordance with good industrial hygiene and safety practice.

#### General hygiene considerations

### 7.2. Conditions for safe storage, including any incompatibilities

#### Storage Conditions

Store as directed by product packaging.

### 7.3. Specific end use(s)

#### Specific use(s)

Pharmaceutical product used as. Antineoplastic.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

##### Tartaric acid

Germany DFG

TWA-MAK: 2 mg/m<sup>3</sup>; I(2);inhalable fraction

Peak: 4 mg/m<sup>3</sup>; inhalable fraction

Germany TRGS

TWA-AGW; 2 mg/m<sup>3</sup> (exposure factor 2); inhalable fraction

Switzerland

TWA-MAK: 2 mg/m<sup>3</sup>; inhalable dust

STEL-KZGW: 4 mg/m<sup>3</sup>; inhalable dust

##### Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

TWA-TMW: 2 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4 mg/m<sup>3</sup> (8 X 5 min); inhalable fraction

Bulgaria

TWA: 2.0 mg/m<sup>3</sup>; alkaline aerosols

Czech Republic

1 mg/m<sup>3</sup>

Ceiling: 2 mg/m<sup>3</sup>

Denmark

Ceiling: 2 mg/m<sup>3</sup>;

Estonia

TWA: 1 mg/m<sup>3</sup>;

STEL: 2 mg/m<sup>3</sup>;

Finland

Ceiling: 2 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 6 / 13

Version 3

France	2 mg/m <sup>3</sup>
Hungary	TWA-AK: 1 mg/m <sup>3</sup> ; STEL-CK: 2 mg/m <sup>3</sup> ;
Ireland	STEL: 2 mg/m <sup>3</sup> ;
Ceiling Limit Value	2 mg/m <sup>3</sup>
Latvia	TWA: 0.5 mg/m <sup>3</sup> ;
Poland	TWA-NDS: 0.5 mg/m <sup>3</sup> ; STEL-NDSCh: 1 mg/m <sup>3</sup> ;
Romania	TWA: 1 mg/m <sup>3</sup> ;
Slovakia	STEL: 3 mg/m <sup>3</sup> ;
Spain	TWA: 2 mg/m <sup>3</sup> ;
Switzerland	STEL (VLA-EC): 2 mg/m <sup>3</sup> ; TWA-MAK: 2 mg/m <sup>3</sup> ; inhalable dust STEL-KZGW: 2 mg/m <sup>3</sup> ; inhalable dust
OSHA PEL	TWA: 2 mg/m <sup>3</sup>
United Kingdom	(vacated) Ceiling: 2 mg/m <sup>3</sup>
<b>Oxaliplatin</b>	STEL: 2 mg/m <sup>3</sup> ;
Austria	TWA-TMW: 0.002 mg/m <sup>3</sup> ; inhalable fraction DS RS
Czech Republic	0.001 mg/m <sup>3</sup>
Finland	Ceiling: 0.002 mg/m <sup>3</sup>
Germany DFG	TWA: 1 mg/m <sup>3</sup> ;
Slovakia	STEL: 3 mg/m <sup>3</sup> ;
Switzerland	pSk DS RS TWA: 0.001 mg/m <sup>3</sup> ; Ceiling: 0.002 mg/m <sup>3</sup> ; TWA-MAK: 0.002 mg/m <sup>3</sup> ; S

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 7 / 13

Version 3

<b>Eye/face protection</b>	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
<b>Hand protection</b>	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
<b>Skin and body protection</b>	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
<b>Respiratory protection</b>	Under normal conditions of use, if the applicable Occupational Exposure Band (OEB) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEB (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
<b>Thermal hazards</b>	No information available.
<b>Environmental exposure controls</b>	No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

<b>Appearance</b>	Solution
<b>Physical state</b>	Liquid
<b>Color</b>	No information available
<b>Odor</b>	Odorless.
<b>Odor threshold</b>	No information available

<b>Property</b>	<b>Values</b>
<b>Melting point / freezing point</b>	No data available
<b>Boiling point or initial boiling point and boiling range</b>	100
<b>Flammability (solid, gas)</b>	No data available
<b>Lower and upper explosion limit/flammability limit</b>	
Lower explosion limit	No data available
Upper explosion limit	No data available
<b>Flash point</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	
SADT (°C)	No data available
<b>pH</b>	4.8-7
pH (as aqueous solution)	No data available
<b>Kinematic viscosity</b>	No data available
Dynamic viscosity	No data available
<b>Solubility</b>	No data available
<b>Vapor pressure</b>	No data available
<b>Density and/or relative density</b>	No data available
Bulk density	No data available
Liquid Density	No data available
<b>Vapor density</b>	No data available
<b>Particle characteristics</b>	
Particle Size	No information available
Particle Size Distribution	No information available

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 8 / 13

Version 3

## 9.2. Other information

**Molecular formula**

Mixture

**Molecular weight**

Mixture

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

**Reactivity**

No information available.

### 10.2. Chemical stability

**Stability**

Stable up to .?°C.

**Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### 10.3. Possibility of hazardous reactions

**Possibility of hazardous reactions** No information available.

### 10.4. Conditions to avoid

**Conditions to avoid**

Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

### 10.5. Incompatible materials

**Incompatible materials**

As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

**Hazardous decomposition products** No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:**

The information included in this section describes the potential hazards of the active ingredient

**Short term**

Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. In the workplace, platinum compounds have been reported to cause allergic skin and respiratory reactions.

**Long Term:**

May cause effects on blood and blood forming organs Repeat-dose studies in animals have shown a potential to cause adverse effects on testes and the developing fetus.

**Known Clinical Effects:**

Adverse effects most commonly reported in clinical use include vomiting, diarrhea, bone marrow suppression, decreased red blood cell count (anemia), decreased white blood cells (leukopenia), decrease in platelets and red/white blood cells (pancytopenia), nervous system/brain toxicity (neurotoxicity), and skin and acute mucous membrane irritation.

**Acute toxicity**

Based on available data, the classification criteria are not met.

**Serious eye damage/eye irritation**

Based on available data, the classification criteria are not met.

**Skin corrosion/irritation**

Based on available data, the classification criteria are not met.

**Respiratory or skin sensitization**

Based on available data, the classification criteria are not met.

**STOT - single exposure**

Based on available data, the classification criteria are not met.

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 9 / 13

Version 3

**STOT - repeated exposure** Based on available data, the classification criteria are not met.  
**Reproductive toxicity** Based on available data, the classification criteria are not met.  
**Germ cell mutagenicity** Based on available data, the classification criteria are not met.  
**Carcinogenicity** Based on available data, the classification criteria are not met.  
**Aspiration hazard** Based on available data, the classification criteria are not met.

## Acute Toxicity: (Species, Route, End Point, Dose)

### Sodium hydroxide

Mouse IP LD50 40 mg/kg

### Oxaliplatin

Rat Oral LD50 > 100 mg/kg

Rat IP LD 50 14.3 mg/kg

Mouse Intraperitoneal LD 50 19.8 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Tartaric acid		> 2000 mg/kg ( Rat )	-
Sodium hydroxide	= 325 mg/kg ( Rat )	= 1350 mg/kg ( Rabbit )	-

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

- 2.5 % of the mixture consists of ingredient(s) of unknown acute toxicity.
- 2.5 % of the mixture consists of ingredient(s) of unknown acute oral toxicity.
- 2.5 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity.
- 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).
- 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas).
- 2.5 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor).

## Irritation / Sensitization: (Study Type, Species, Severity)

### Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

### Oxaliplatin

Eye Irritation ( *In vitro* , BCOP) Irritant

Skin Irritation ( *In vitro* , RhE) Negative

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Oxaliplatin

Fertility and Embryonic Development Rat No route specified 1 mg/kg/day NOAEL Fetotoxicity

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Oxaliplatin

Bacterial Mutagenicity (Ames) *Salmonella* Negative

*In Vitro* Mammalian Cell Mutagenicity Mouse Lymphoma Positive

*In Vitro* Chromosome Aberration Human Lymphocytes Positive

*In Vivo* Micronucleus Mouse Bone Marrow Positive

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 10 / 13

Version 3

## 11.2.2. Other information

**Other adverse effects** No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

**Unknown aquatic toxicity** Contains 2.5 % of components with unknown hazards to the aquatic environment.

### 12.1. Toxicity

**No information available**

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment**

Chemical name	PBT and vPvB assessment
Tartaric acid	Not PBT/vPvB
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 11 / 13

Version 3

and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

<b>UN number:</b>	Not applicable
<b>UN proper shipping name:</b>	Not applicable
<b>Transport hazard class(es):</b>	Not applicable
<b>Packing group:</b>	Not applicable
<b>Environmental Hazard(s):</b>	Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### Water

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-791-2
<b>AICS</b>	Present

#### Tartaric acid

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	201-766-0
<b>AICS</b>	Present

#### Sodium hydroxide

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	1000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	215-185-5
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

#### Oxaliplatin

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 4

### National regulations

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 12 / 13

Version 3

## Germany

### **Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

## **TRGS 905**

Not applicable

## Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material** Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable

**Major Accidents Ordinance SR 814.012** Not applicable

## **European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

### **Authorizations and/or restrictions on use:**

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide 1310-73-2	75	-

## **Persistent Organic Pollutants**

Not applicable

## **Ozone-depleting substances (ODS) Regulation (EU) 2024/590**

Not applicable.

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
Tartaric acid 87-69-4	Simplified procedure - Category 1

## **Explosives Precursors Marketing and Use (2019/1148)**

Not applicable

## Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

# SAFETY DATA SHEET

Product Name Oxaliplatin Injection (Solution for Intravenous Use)  
(Hospira Inc.)  
Revision date 13-Jun-2025

Page 13 / 13

Version 3

## 15.2. Chemical safety assessment

### Chemical Safety Report

No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage. H340 - May cause genetic defects. H360D - May damage the unborn child.

#### Data Sources:

Pfizer proprietary drug development information. Publicly available toxicity information.

#### Reason for revision

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

#### Revision date

13-Jun-2025

#### Prepared By

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.